Supernus Pharmaceuticals, Inc.
S&P 600
$41.64
-0.12%
Delayed · cached 15 min
Price Chart
Price50-day avg200-day avg
How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.
✓Strengths
- Current assets comfortably cover current liabilities (current ratio 1.9).
!Watch-points
- Return on equity is on the lower side at -3.7%.
- Return on capital employed is on the lower side at -5.7%.
- The company reported a net loss in the latest period.
These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.
Forensic Checks
Altman Z-ScoreSafe zone
4.73
In Altman’s original study, companies in this range showed a low incidence of financial distress.
Piotroski F-ScoreModerate
4 / 7
The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.
Based on 7 of the 9 signals — the rest need data not available for this stock.
These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.
Key Ratios
Market Cap$2.42B
Current Price$ 41.64
High / Low$ 59.68 / 41.11
Stock P/E-61.24
Book Value$ 17.76
Dividend Yield0%
ROCE-5.71%
ROE-3.74%
Current Ratio1.90
P/B Ratio2.3485618
EPS$ -0.68
PAT Margin-5.36%
Cash PAT$53.01M